

Major Trial Results Livestream: Anticoagulation in COVID-19

By CCMB Communications & Public Affairs

August 4, 2021 11:42 AM



Critical Care Reviews Trial Results Meeting
Multiplatform Therapeutic Anticoagulation in Moderate and Severe COVID-19

EDT (UTC-4)

16:30	Background	Ewan Goligher
16:40	Statistical Plan	Lindsay Berry
16:50	Results	Patrick Lawler
17:00	Editorial	Charlotte Summers
17:10	Reply to Editorial	Ryan Zarychanski
17:15	Questions	Open to Viewers
17:25	Panel Discussion	Ryan Zarychanski Lindsay Berry Charlotte Summers Judith Hochman Saskia Middelorp Jim Doukeris
18:00	End	

Wednesday August 4th

Toronto	16:30 to 18:00	Sydney (5th)	06:30 to 08:00	Nairobi	21:30 to 01:00
Winnipeg	15:30 to 17:00	Beijing (5th)	04:30 to 06:00	Rome	22:30 to 00:00
San Francisco	13:30 to 15:00	Mumbai (5th)	02:00 to 03:30	Dublin	21:30 to 23:00

<https://criticalcarereviews.com>

ATTACC ACTIV-4

The ACTIV4-a, ATTACC, & REMAP-CAP investigators will present the results of this multi-platform trial, in which critically ill adults were randomized to receive therapeutic anticoagulation with heparin or pharmacological thromboprophylaxis as per local usual care.

This live webcast includes a description on how the trial was done and what the role of therapeutic anticoagulation is in hospitalized patients with COVID-19, our results, an independent editorial and a panel discussion. The webcast can be accessed via the link below:

<https://criticalcarereviews.com/livestreams/covid-19-anticoagulation> (<https://criticalcarereviews.com/livestreams/covid-19-anticoagulation>)

Date: Wednesday, August 4, 2021

Time: 15h30 Winnipeg (approximately 90 minutes)

Registration is free.